Further to an earlier posting about Merck and Elsevier combining on a fake journal, Elsevier now acknowledges that there were six "sponsored article publications."
Elsevier Published Six Fake Journals
May 8, 2009
Share this post
2 Comments

Law Bytes
Episode 254: Looking Back at the Year in Canadian Digital Law and Policy
byMichael Geist

December 22, 2025
Michael Geist
December 8, 2025
Michael Geist
December 1, 2025
Michael Geist
November 24, 2025
Michael Geist
November 17, 2025
Michael Geist
Search Results placeholder
Recent Posts
The Year in Review: Top Ten Michael Geist Substacks
The Year in Review: Top Ten Law Bytes Podcast Episodes
The Year in Review: Top Ten Posts
The Law Bytes Podcast, Episode 254: Looking Back at the Year in Canadian Digital Law and Policy
Confronting Antisemitism in Canada: If Leaders Won’t Call It Out Without Qualifiers, They Can’t Address It

Use bugmenot to read the article
If you do not want to register just to read an article, use bugmenot.com to enter the-scientist site.
Sick and tired of walled gardens like Elsevier? Support Science Commons
http://sciencecommons.org/about/
Quote:
There are petabytes of research data being produced in laboratories around the world, but the best web search tools available can’t help us make sense of it. Why? Because more stands between basic research and meaningful discovery than the problem of search.
Many scientists today work in relative isolation, left to follow blind alleys and duplicate existing research. Data are balkanized — trapped behind firewalls, locked up by contracts or lost in databases that can’t be accessed or integrated. Materials are hard to get — universities are overwhelmed with transfer requests that ought to be routine, while grant cycles pass and windows of opportunity close. It’s not uncommon for research sponsors to invest hundreds of millions of dollars in critically important efforts like drug discovery, only to see them fail.
The consequences in many cases are no less than tragic. The time it takes to go from identifying a gene to developing a drug currently stands at 17 years — forever, for people suffering from disease.